Addis Ababa ‒ Fourteen-year-old girl Saba. D. (name changed), from Ethiopia’s capital, Addis Ababa, has just received her first and final dose of the human papillomavirus (HPV) vaccine, which protects against cervical cancer. This cancer is the second most common cancer among women in Ethiopia after breast cancer and each year significant number of women die from it.
    •  Otter   ( @otter@lemmy.ca ) OP
      5•7 months ago

      This is a community for public health, and the article is about a vaccination campaign that just happened in that country. It’s not relevant for everyone, but it can be relevant for people working in the field.

      Saba is one of the 1.5 million 14-year-old girls who were vaccinated in early March 2024, as part of a four-day nationwide vaccination campaign. The HPV vaccine is being administered using a campaign mode by availing vaccination for four consecutive days at fixed vaccination posts and temporary fixed vaccination posts at schools where most of the target age group, 14-year-age girls, are easily found.

      Based on the MoH decision and the country’s National Immunization Technical Advisory Groups, the two-dose schedule used over the past five years was switched to a single-dose schedule for the primary target group, girls aged 14 years. The decision was based on the evidence which indicated that a single-dose schedule provides solid protection with a comparable efficacy to the two or three-dose schedules. This evidence has also been evaluated and recommended by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) in 2022.

      I’m open to suggestions if you want to see other types of updates in this community (ex. the research articles).

      If the problem is that you don’t like seeing posts from !publichealth@mander.xyz in your feed, you can block the community